Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research focused on Idiopathic pulmonary fibrosis and Pirfenidone, with related work in Minimal clinically important difference, Pulmonary fibrosis, Clinical endpoint. Notable publications include 'A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis', '6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis', and 'All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials'.
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials
Comprehensive assessment of the long‐term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis